Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strattera in Comorbid ADHD and PTSD
NCT02287038Phase 4Completed
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by VA Office of Research & Development. Started Oct 2014; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02287038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287038.